Date: 2011-12-30
Type of information: Private placement
Company: Amsterdam Molecular Therapeutics (the Netherlands)
Investors: Forbion Capital Partners (The Netherlands) - Gilde Healthcare Partners (The Netherlands) - Advent Venture Partners (UK)
Amount: €2.5 million
Funding type: private placement
Planned used: The proceeds of this issue will provide additional flexibility to further explore its strategic options to secure the financial stability of the Company. The proceeds do not eliminate the Company\\\'s negative equity position, which will continue after completion of the equity raising, which is expected to take place on or around January 4, 2012, and the Company\\\'s financial prospects remain as described in the announcement of December 15, 2011.
Others: Amsterdam Molecular Therapeutics has raised €2.5 million in new equity by means of a private placement to three of its existing shareholders: Forbion Capital Partners, Gilde Healthcare Partners and Advent Venture Partners. Under the terms of the transaction, AMT has agreed to issue 7,352,938 new shares at a price of € 0.34 per share, being the closing price on December 29, 2011, when the shares were placed. As a result of the private placement, the Company\\\'s issued share capital will amount to 31,051,454 shares.
Therapeutic area: Rare diseases - Genetic diseases
